Nothing Special   »   [go: up one dir, main page]

AR123924A1 - Células nk con receptores de antígeno quimérico (car) y usos de estas - Google Patents

Células nk con receptores de antígeno quimérico (car) y usos de estas

Info

Publication number
AR123924A1
AR123924A1 ARP210102971A ARP210102971A AR123924A1 AR 123924 A1 AR123924 A1 AR 123924A1 AR P210102971 A ARP210102971 A AR P210102971A AR P210102971 A ARP210102971 A AR P210102971A AR 123924 A1 AR123924 A1 AR 123924A1
Authority
AR
Argentina
Prior art keywords
cell
car
polynucleotide sequence
crispr
plasmid
Prior art date
Application number
ARP210102971A
Other languages
English (en)
Inventor
Meisam Naeimi Kararoudi
Dean Anthony Lee
Original Assignee
Res Institute At Nationwide Children’S Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Institute At Nationwide Children’S Hospital filed Critical Res Institute At Nationwide Children’S Hospital
Publication of AR123924A1 publication Critical patent/AR123924A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un plásmido para usar con sistemas asociados a repeticiones palindrómicas cortas agrupadas y espaciadas de forma regular (CRISPR) / proteína 9 asociada a CRISPR (Cas9) caracterizado porque el plásmido comprende en orden un brazo de homología izquierdo, una secuencia polinucleotídica que codifica un polipéptido del receptor de antígeno quimérico (CAR) y un brazo de homología derecho; donde los brazos de homología izquierdo y derecho tienen cada uno 1000 bp de longitud o menos. Reivindicación 16: Un vector viral adenoasociado (AAV) caracterizado porque comprende el plásmido de una cualquiera de las reivindicaciones 1 a 15. Reivindicación 22: Una célula modificada que comprende el plásmido de una cualquiera de las reivindicaciones 1 a 15 o el vector AAV de una cualquiera de las reivindicaciones 16 a 21. Reivindicación 27: Un método para modificar genéticamente una célula caracterizado porque comprende a) obtener un complejo de ribonucleoproteína (RNP) que comprende una endonucleasa CRISPR / Cas de clase 2 (Cas9) complejada con un RNA guía CRISPR / Cas correspondiente y un vector AAV que comprende un plásmido que comprende una secuencia polinucleotídica que codifica un polipéptido del receptor de antígeno quimérico (CAR); donde la secuencia de polinucleótidos está flanqueada por brazos de homología; y donde los brazos de homología tienen una longitud de 800 bp o menos; y b) introducir la secuencia de polinucleótidos que codifica el polipéptido CAR y el complejo RNP en la célula; donde la secuencia de polinucleótidos que codifica el polipéptido CAR se introduce en la célula a través de la infección con el AAV en la célula; donde el complejo RNP se hibrida con una secuencia dirigida dentro del DNA genómico de la célula y las enzimas de reparación del DNA de la célula insertan la secuencia polinucleotídica que codifica el polipéptido CAR en el genoma del hospedador en la secuencia dirigida dentro del DNA genómico de la célula creando así una célula modificada. Reivindicación 51: Un método para crear una célula citolítica natural (NK) del receptor de antígeno quimérico (CAR) o una célula T CAR NK caracterizado porque comprende a) obtener un complejo de ribonucleoproteína (RNP) que comprende una endonucleasa CRISPR / Cas de clase 2 (Cas9) complejada con un RNA guía CRISPR / Cas correspondiente y un vector AAV que comprende un plásmido que comprende una secuencia polinucleotídica que codifica un polipéptido del receptor de antígeno quimérico (CAR); donde la secuencia de polinucleótidos está flanqueada por brazos de homología; y donde los brazos de homología tienen una longitud de 1000 bp o menos; e b) introducir la secuencia de polinucleótidos que codifica el polipéptido CAR y el complejo RNP en una célula NK o una célula T NK; donde la secuencia de polinucleótidos que codifica el polipéptido CAR se introduce en la célula NK o célula T NK a través de la infección con el AAV en la célula NK o célula T NK; donde el complejo RNP se hibrida con una secuencia dirigida dentro del DNA genómico de la célula NK o célula T NK y las enzimas reparadoras del DNA de la célula NK o célula T NK insertan la secuencia de polinucleótidos que codifica el polipéptido CAR en el genoma del hospedador en la secuencia dirigida dentro del DNA genómico de la célula creando así una célula CAR NK o una célula T CAR NK. Reivindicación 97: Un plásmido para usar con sistemas asociados a repeticiones palindrómicas cortas agrupadas y espaciadas de forma regular (CRISPR) / proteína 9 asociada a CRISPR (Cas9) caracterizado porque el plásmido comprende una secuencia de polinucleótidos que codifica un polipéptido del receptor de antígeno quimérico (CAR); donde la secuencia de polinucleótidos es adyacente a un motivo adyacente protoespaciador (PAM) y una secuencia de polinucleótidos que codifica RNA crispr (crRNA) o flanqueada por dos PAM y dos secuencias de polinucleótidos que codifican crRNA. Reivindicación 105: Un vector viral adenoasociado (AAV) caracterizado porque comprende el plásmido de una cualquiera de las reivindicaciones 97 a 104. Reivindicación 109: Una célula modificada que comprende el plásmido de una cualquiera de las reivindicaciones 97 a 104 o el vector AAV de una cualquiera de las reivindicaciones 105 a 108. Reivindicación 114: Un método para crear una célula asesina natural (NK) o célula T NK del receptor de antígeno quimérico (CAR) caracterizado porque comprende a) obtener un complejo de ribonucleoproteína (RNP) que comprende una endonucleasa CRISPR / Cas de clase 2 (Cas9) complejada con un RNA guía CRISPR / Cas correspondiente y un vector AAV que comprende un plásmido que comprende una secuencia de polinucleótidos que codifica un receptor de antígeno quimérico (CAR); donde la secuencia de polinucleótidos es adyacente a un motivo adyacente protoespaciador (PAM) y una secuencia de polinucleótidos que codifica RNA crispr (crRNA) o flanqueada por dos PAM y dos secuencias de polinucleótidos que codifican crRNA; y b) introducir la secuencia de polinucleótidos que codifica el polipéptido CAR y el complejo RNP en la célula NK o célula T NK; donde el plásmido se introduce en la célula a través de la infección con el virus adenoasociado (AAV) en una célula efectora; donde el complejo de ribonucleoproteína (RNP) se hibrida con una secuencia dirigida dentro del DNA genómico de la célula, y las enzimas de reparación del DNA de la célula insertan el polinucleótido que codifica el CAR en el genoma del hospedador en la secuencia dirigida, creando así una célula CAR NK o célula T CAR NK. Reivindicación 116: Un método para modificar genéticamente una célula asesina natural (NK) o una célula T NK caracterizado porque comprende a) obtener un complejo de ribonucleoproteína (RNP) que comprende una endonucleasa CRISPR / Cas de clase 2 (Cas9) complejada con un RNA guía CRISPR / Cas correspondiente y un vector AAV que comprende un plásmido que comprende una secuencia de polinucleótidos que codifica un receptor de antígeno quimérico (CAR); donde la secuencia de polinucleótidos es adyacente a un PAM y una secuencia de polinucleótidos que codifica crRNA o flanqueada por dos PAM y dos secuencias de polinucleótidos que codifican crRNA; y b) introducir la secuencia de polinucleótidos que codifica el polipéptido CAR y el complejo RNP en la célula NK o célula T NK; donde la secuencia de polinucleótidos que codifica el polipéptido CAR se introduce en la célula a través de la infección con el virus adenoasociado (AAV) en una célula efectora; donde el complejo de ribonucleoproteína (RNP) se hibrida con una secuencia dirigida dentro del DNA genómico de la célula, y las enzimas de reparación del DNA de la célula insertan la secuencia polinucleotídica que codifica el receptor de antígeno quimérico (CAR) en el genoma del hospedador en la secuencia dirigida, creando así una célula modificada.
ARP210102971A 2020-10-26 2021-10-26 Células nk con receptores de antígeno quimérico (car) y usos de estas AR123924A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063105722P 2020-10-26 2020-10-26

Publications (1)

Publication Number Publication Date
AR123924A1 true AR123924A1 (es) 2023-01-25

Family

ID=81256896

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102971A AR123924A1 (es) 2020-10-26 2021-10-26 Células nk con receptores de antígeno quimérico (car) y usos de estas

Country Status (12)

Country Link
US (1) US20220127644A1 (es)
EP (1) EP4232560A1 (es)
JP (1) JP2023552917A (es)
KR (1) KR20230089570A (es)
CN (1) CN117136232A (es)
AR (1) AR123924A1 (es)
AU (1) AU2021372458A1 (es)
CA (1) CA3196656A1 (es)
IL (1) IL302335A (es)
MX (1) MX2023004811A (es)
TW (1) TW202233829A (es)
WO (1) WO2022093863A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024124243A2 (en) * 2022-12-09 2024-06-13 Research Institute At Nationwide Children's Hospital Chimeric antigen receptor (car) t cells and uses thereof
WO2024129984A1 (en) * 2022-12-15 2024-06-20 The Board Of Trustees Of The Leland Stanford Junior University Homology-independent targeted dna insertion in human t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517415A (ja) * 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド がんを処置するための改変ｎｋ−９２細胞
EP3634493A1 (en) * 2017-05-08 2020-04-15 Precision BioSciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
EP3802825A1 (en) * 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
KR20210096088A (ko) * 2018-10-17 2021-08-04 크리스퍼 테라퓨틱스 아게 전이유전자 전달용 조성물 및 방법
SG11202110613SA (en) * 2019-03-27 2021-10-28 Res Inst Nationwide Childrens Hospital Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses

Also Published As

Publication number Publication date
EP4232560A1 (en) 2023-08-30
WO2022093863A1 (en) 2022-05-05
TW202233829A (zh) 2022-09-01
AU2021372458A9 (en) 2024-04-18
MX2023004811A (es) 2023-06-29
CN117136232A (zh) 2023-11-28
US20220127644A1 (en) 2022-04-28
IL302335A (en) 2023-06-01
AU2021372458A1 (en) 2023-06-15
KR20230089570A (ko) 2023-06-20
CA3196656A1 (en) 2022-05-05
JP2023552917A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
JP7418957B2 (ja) タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法
JP2021118726A5 (es)
JP6932698B2 (ja) アルファ１アンチトリプシン欠乏症の治療のための材料および方法
Huang et al. Novel CRISPR/Cas applications in plants: from prime editing to chromosome engineering
JP2022095663A5 (es)
JP2019508051A5 (es)
RU2018124657A (ru) Способы редактирования генов и композиции для устранения риска активации вируса jc и пмл (прогрессирующая мультифокальная лейкоэнцефалопатия) во время иммуносупрессивной терапии
JP2017505117A5 (es)
JP2018138054A5 (es)
AR123924A1 (es) Células nk con receptores de antígeno quimérico (car) y usos de estas
FI3445388T3 (fi) Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
Wu et al. TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus
WO2015153791A1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
JP2021500072A (ja) 血友病ａに対する遺伝子編集用組成物及び方法
AR103245A1 (es) Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
US20220251580A1 (en) Improved gene editing system
CN104560995A (zh) 一对特异识别猪H11位点的sgRNA及其编码DNA和应用
CN105602972B (zh) 基于CRISPR-Cas9体外改造腺病毒载体的方法
US20230149439A1 (en) Rho-adrp gene editing-based methods and compositions
US20230310555A1 (en) Compositions for genome editing and methods of use thereof
CN112626070A (zh) 一种基于切离酶基因编辑技术的定向修复系统
JP2023553422A (ja) ウイルスゲノムを切断するための組成物及び方法
Epstein et al. 119. Engineering a self-inactivating CRISPR system for AAV vectors
RU2021131306A (ru) Получение первичных nk-клеток с химерными антигенными рецепторами (car) для иммунотерапии онкологических заболеваний с использованием комбинации cas9/рнп и вирусов aav
WO2023232024A1 (en) System and methods for duplicating target fragments